Effects and kinetics of anti–c-kit monoconal antibody ACK-2 on hematopoiesis and hematopoietic progenitors and its ability to condition for bone marrow transplantation  by Kraft, D.L. & Weissman, I.L.
stem cells into endothelial cells. The stem cells were derived from
bone marrow by CD34 selection, and were stimulated with either
m-CSF or PTN alone or a combination of m-CSF and PTN or no
treatment for 7 days. Real-time PCR analysis showed that the
m-CSF and PTN combination markedly increased endothelial cell
marker expression and decreased monocyte marker (CD68 and
c-fms) expression in this stem cell population. When induced with
PTN alone, the stem cells exhibited slightly increasing expression
of endothelial markers. These experiments deﬁne a previously
unrecognized novel mechanism leading to angiogenesis in cancer
patients: the transdifferentiation of monocytes into endothelial
cells by a factor highly produced by tumor cells. They also suggest
a potential new speciﬁc target to inhibit angiogenesis—pleiotro-
phin—which may have profound clinical implications.
253
BONE MARROW STEM CELL TRANSPLANTATION IN NEURODEGENERA-
TIVE AND CEREBROVASCULAR DISEASE: PRELIMINARY REPORT
Ozbabalik, D.B., Gulbas, Z., Adapinar, B., Ak, I., Gulel, B. Osmangazi
University Medical Faculty, Eskisehir, Turkey.
Stem cells with self-renewal and multilineage potential are con-
sidered good candidates for cell replacement of damaged nervous
tissue in cerebrovascular and neurodegenerative disease. Most of
the knowledge about the role of stem cells in the progression of
these diseases have been based on experimental evidence. Until
now, there has been no human study showing the effectiveness of
stem cell transplantation in neurologic disease. In this study we
attempted to test whether bone marrow stem cells can improve the
functional, radiologic, and metabolic outcomes in patients with
vascular dementia and ischemic stroke with intra-arterial injection.
Seven patients, (3 female and 4 male; mean age  SD, 68.23 
11.2 years) were included in the study. Patients were selected from
among chronic poststroke and/or vascular dementia patients who
did not respond to classical therapy. Barthel, NIH, and MMSE
scales were used to record mental and motor status, and MR and
SPECT were used to record radiologic and metabolic status before
and 30, 60 and 120 days after the procedure. After the patients were
given neurologic examinations, their bone marrow was aspirated,
cultured in Teﬂon bags, and proliferated during 24 hours. Cul-
tured bone marrow was given to patients intra-arterially and an-
giographically under sterile conditions.
Functionally and mentally, all patients showed improvement in
Barthel, NIH, and MMSE scales 60 days after the procedure, but
the differences were not statistically signiﬁcant (ﬁrst Barthel,
9.85 2.67, last Barthel, 11.28 2.69, [P .32]; ﬁrst NIH, 9.00
2.63, last NIH, 7.42  2.19 [P  .16]; ﬁrst MMSE, 10.71  3.73,
last MMSE, 17.00 4.69 [P  .63]).
In terms of radiology, volumetric improvement on MR was seen
after the procedure (Cavalier volumetric method; P  .047). On
SPECT, cerebral metabolism was observed to increase in 3 patients
quantatively. Finally, we observed a trend of clinical improvement in
our patients. But our study has some limitations, such as a small
number of patients. Nonetheless, in light of our ﬁrst results, we can
say that otology bone marrow stem cell transplantation may provide
new hope in the treatment of neurodegenerative disease.
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BIOLUMINESCENT TRACKING OF CANDIDATE LEUKEMIC STEM CELL
ENGRAFTMENT IN IMMUNOCOMPROMISED MICE
Jamieson, C.H.M., Karimi, M., Creusot, R., Fathman, C.G.,
Negrin, R., Weissman, I.L. Stanford University School of Medicine,
Stanford, CA.
Background: We investigated whether leukemic stem cells
(LSCs) involved in CML progression use the beta-catenin pathway
for self-renewal and also whether inhibition of beta-catenin with
axin prevents engraftment of leukemic stem cells in an immuno-
compromised mouse model using bioluminescent tracking. Meth-
ods: We used ﬂuorescence-activated cell sorting (FACS) to isolate
hematopoietic stem cells (HSCs), common myeloid progenitors
(CMPs), granulocyte/macrophage progenitors (GMPs), and
megakaryocyte/erythroid progenitors (MEPs) from normal mar-
row, cord blood, or advanced-phase CML. In vitro replating assays
were used to identify self-renewing cells as candidate leukemic
stem cells, and the dependence of self-renewal on beta-catenin
activation was tested by lentiviral transduction of hematopoietic
progenitors with axin, an inhibitor of the beta-catenin pathway.
CML HSCs, CMPs, GMPs, or CD3438 cells were transduced
with a lentiviral luciferase GFP vector with or without axin, trans-
planted intrahepatically into newborn T-, B-, and NK-deﬁcient
mice and monitored for engraftment via weekly bioluminescent
imaging as well as tail bleeding to detect GFP-positive cells. Re-
sults: When compared with normal marrow, the GMP pool from
patients in blast crisis and imatinib-resistant CML was expanded
and had elevated levels of nuclear beta-catenin. Unlike normal
GMPs, CML GMPs formed self-renewing replatable myeloid col-
onies, and in vitro self-renewal capacity was reduced by enforced
expression of axin. Although CML HSC showed evidence of early
engraftment, committed progenitors, such as GMP, expanded
more readily in vivo. and their growth was inhibited by pretreat-
ment with axin. Conclusions: Activation of beta-catenin in CML
granulocyte/macrophage progenitors likely enhances their self-
renewal and leukemic activity. Speciﬁc beta-catenin inhibitors such
as axin block this aberrant self-renewal activity in vitro and in vivo.
Finally, the use of bioluminescent imaging of leukemic/cancer
stem cell engraftment in vivo using a newborn immunocompro-
mised mouse model provides a robust tool for assessing response of
cancer stem cells to molecularly targeted therapy.
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EFFECTS AND KINETICS OF ANTI–C-KIT MONOCONAL ANTIBODY
ACK-2 ON HEMATOPOIESIS AND HEMATOPOIETIC PROGENITORS AND
ITS ABILITY TO CONDITION FOR BONE MARROW TRANSPLANTATION
Kraft, D.L., Weissman, I.L. Stanford University School of Medicine,
Stanford University, CA.
Background: The stem cell receptor factor receptor c-Kit is ex-
pressed on hematopoeitic stem cell (HSC) and progenitor cell popu-
lations. ACK-2 is an anti-mouse c-kit mAb that has been shown to
antagonize the function of c-kit and deplete the bone marrow of
treated mice. We wished to characterize the effect and kinetics of
ACK-2 on the peripheral blood cell counts and marrow HSC and
progenitor populations. We also tested the hypothesis that treatment
with ACK-2 may serve as a novel means of nonmyeloablative condi-
tioning for HSC transplantation.Methods: Adult C57/BLmice were
injected either intravenously or intraperitonealy (IP) with 1 mg of
ACK2 mAb on days 0, 2, and 4. Peripheral blood cell counts, includ-
ing WBC differentials, were followed over time in recipient mice.
Peripheral blood and bonemarrow was analyzed at day 7, andmarrow
was analyzed for fraction and proportions of HSC, common myeloid
progenitors (CMPs), granulocyte macrophage progenitors (GMPs),
and macrophage erythrocyte progenitors (MEPs). A subset of Ly5.1
mice that had received ACK2mAb on days 0, 2, and 4 received a bone
marrow transplantation on day 7 with 1106 bone marrow cells from
a congenic Ly5.2 donor. Results: Both IV and IP administration of
ACK-2 resulted in rapid development of anemia, neutropenia, and
thrombocytopenia (see the table for results). Analysis of peripheral
blood revealed a decrease in Mac-1 cells from 12.2% of circulating
WBCs in untreated controls to 3.1% at day 7, whereas the proportion
of B220 B cells increased frommean of 49.7% in controls to 72.7%.
The fraction of circulating T cells decreased from 24.5% to 11.1% at
day 7. The bone marrow fraction of KTLS HSC decreased from
0.07% of total marrow cells in controls to 0.003% in ACK-2–treated
mice. The marrow fractions of CMP and GMP all decreased in
treatedmice, with a proportional drop in CMP progenitors from 12%
in untreated mice to 4.7% in treated mice. ACK-2–treated mice
transplanted with Ly5.2 congenic marrow and analyzed at D21
showed no evidence of donor-derived cells in the peripheral blood,
compared with 83% Ly5.2 donor-derived cells in control mice re-
ceiving 9 Gy of radiation. Coclusions: The anti–c-kit mAb ACK-2
rapidly induces anemia, neutropenia, and thrombocytopenia with cor-
relating decreases in the numbers of marrow HSC and other progen-
itor populations. Despite the ablative action of the ACK-2 on marrow




Table 1. Effect of Anti c-Kit mAb on Peripheral Blood Cell Counts
Day 0
Control Day 2 Day 4 Day 7 Day 11
WBC 12.1 6.6 4.2 2.6 9.5
Hgb 15.1 14.5 13.2 6.2 5.3
ANC 796 180 32 26 320
Platelet Count 1107 1182 1098 763 220
Mice injected with 1 mg ACK-2 intravenously on Days 0, 2 & 4.
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EPITHELIAL CHIMERISM IN THE ORAL MUCOSA AFTER HUMAN HEMA-
TOPOIETIC CELL TRANSPLANTATION
Spyridonidis, A., Zeiser, R., Metaxas, Y., Faber, P., Finke, J. Freiburg
University Medical Center, Freiburg, Germany.
Several study groups have reported on a nonhematopoietic chi-
merism following allogeneic hematopoietic cell transplantation
(aHCT) both in animals and humans. We recently investigated this
phenomenon in humans and described the pitfalls of identiﬁcation
of epithelial chimerism (Spyridonidis et al, Am J Pathol 164:1147–
1155, 2004). The purpose of the present study was to examine
epithelial chimerism in single cells isolated from the oral mucosa.
Buccal scrapings obtained from 13 female patients who underwent
a sex-mismatched aHCT were employed to prepare cytospins. The
examination was performed 75–1964 days after aHSCT. At this
time point, no patient had signs of mucositis or oral GvHD.
Cytospin preparations were examined with a combination of FISH
for the Y or the XY chromosome; immunoﬂuorescent stain for the
epithelial-speciﬁc marker cytokeratin (CK), for CD45, and Drag
cell nuclei stain; with APAAP immunocytochemistry using either
CD15-, CD45-, CD68-, or CD3-speciﬁc antibodies; and with
hematoxylin and eosin (HE) staining. Evaluation of epithelial chi-
merism was performed with laser scanning confocal microscopy
from examiners who were not aware of the patients’ present or past
medical history. CD45 or CD3 cells were found in 4 patients
with a frequency of  1%. No CD68 or CD15 positive mac-
rophages were detected. In the FISH-Y combined stains, we de-
tected Y/CK/CD45 cells in 12 of 13 patients (92%), with a
mean of 1.8% Y/CK/CD45 cells per 200 total cells analyzed
(range, 0.5%-7.3%). The identiﬁed Y/CK/CD45 cells were
counterstained with HE and revealed an epithelial morphology.
Screening of 5 patients with XY stain demonstrated all Y cells of
them having only 1 X chromosome, making fusion as the under-
lying mechanism unlikely. We retrospectively reviewed the trans-
plantation documents of every patient and found a signiﬁcant
correlation (P value  .0028) between the severity of mucositis in
the early posttransplantation period (up to day 30) and the
degree of epithelial chimerism found at later time points (days
75- 1964), where no signs of mucositis were present. We
conclude that epithelial chimerism of the oral mucosa is a real
phenomenon after aHSCT. Further molecular investigation on a
single-nucleus level and analysis of greater number of transplanted
patients are needed to understand the underlying mechanisms
responsible for generation of the donor derived epithelial cells.
Tissue injury seems to play a role in these mechanisms.
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PEGFILGRASTIM VERSUS FILGRASTIM TO ACCELERATE HEMATOPOI-
ETIC RECOVERY AFTER HIGH-DOSE MELPHALAN AND AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) FOR MULTI-
PLE MYELOMA
Olin, R.L., Luger, S.M., Porter, D.L., Schuster, S.J., Tsai, D.,
Nasta, S., Perl, A., Loren, A.W., Goldstein, S., Mangan, P., Sherry, V.,
Cunningham, K., Sachs, B., Hummel, K., Stadtmauer, E.A. Bone
Marrow and Stem Cell Transplant Program, University of Pennsylva-
nia, Philadelphia, PA.
High-dose melphalan followed by ASCT is a common compo-
nent of the early treatment for multiple myeloma. Daily subcuta-
neous injections of ﬁlgrastim (Neupogen) at 5 g/kg/day until
ANC  500/L are routinely administered at our center from day
4 following ASCT, to accelerate hematopoietic recovery and
lessen neutropenic complications. Pegﬁlgrastim (Neulasta) as a
single 6-mg ﬁxed dose via subcutaneous injection has been shown
to have similar efﬁcacy and ease of use as ﬁlgrastim in the non-
transplantation setting, but little data are available in the transplan-
tation setting. We began using pegﬁlgrastim on day 1 following
ASCT for patients with multiple myeloma and performed a retro-
spective cohort study comparing those who received ﬁlgrastim (the
ﬁlgrastim group [FG]; n  6) with those who received pegﬁlgras-
tim (the pegﬁlgrastim group [PG]; n  11). Transplantations
occurred between July 2002 and January 2004 and included all
patients transplanted for myeloma in that period for whom sufﬁ-
cient data were available. All patients had peripheral stem cells
harvested after cytoxan/ﬁlgrastim mobilization. Main outcome
measures were days from stem cell infusion to WBC nadir, days to
ANC  500/L, and days to ANC  1000/L. Subjects were
excluded if CBCs were drawn less often than every 4 days. There
were no signiﬁcant differences between the FG and the PG with
respect to the following variables: age, gender, hemoglobin, creat-
inine, calcium, albumin, beta-2 microglobulin, number of prior
lines of therapy, and number of CD34 cells infused. After trans-
plantation, the median number of days to WBC nadir was 7 (range,
5–9) in the FG and 6 (range, 5–8) in the PG (P  .31). However,
median number of days to ANC 500/L was 11.5 (range, 11–17)
in the FG and 10 (range, 9–12) for the PG (P  .02). Similarly,
median number of days to ANC  1000/L was 12 (range, 11–17)
for the FG and 11 (range, 10–13) for the PG (P  .03). Five of 6
patients in the FG had neutropenic fever after transplantation,
compared with 5 of 11 patients in the PG (P  .30). Currently, no
signiﬁcant differences in infection or relapse rates between the
groups was noted, and there were no deaths in either group. In this
retrospective cohort study, pegﬁlgrastim was safe and at least
equivalent to ﬁlgrastim for accelerating hematopoiesis after ASCT
for multiple myeloma. Furthermore, there was no signiﬁcant dif-
ference in the incidence of neutropenic fever, infection, and sur-
vival, suggesting a similar clinical utility.
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VANGANCICLOVIR PROPHYLAXIS FOR THE PREVENTION OF CYTO-
MEGALOVIRUS REACTIVATION AND DISEASE IN ALLOGENEIC STEM
CELL TRANSPLANTATION RECIPIENTS
Magalhaes-Silverman, M., Carter, T., Hohl, R., Shamsuddin, H.,
Gingrich, R. University of Iowa, Iowa City, IA.
Background: CMV infection continues to be an important cause
of morbidity and mortality after allogeneic stem cell transplanta-
tion. Valganciclovir (VGC), the valine ester of ganciclovir, has
excellent oral bioavailability and has the potential to replace intra-
venous ganciclovir in many situations, namely CMV prophylaxis or
preemptive therapy after allogeneic transplantation. Methods:
From October 2002 to April 2004, 34 patients who were either
CMV seropositive or had a seropositive donor were enrolled in
prospective trial of intravenous (IV) ganciclovir at 5 mg/kg twice a
day for 1 week, followed by oral VGC 900 mg twice a day for a
total of 180 days. IV ganciclovir was started at time of engraftment.
Dose adjustments of VCG were made according to renal function,
and growth factors were allowed in the event of neutropenia. Study
endpoints included incidence of CMV reactivation and disease
during the ﬁrst 180 days after transplantation. For the study,
viremia was deﬁned as a positive CMV blood culture by shell vial
or conventional culture. A positive antigenemia assay in patients
with severe (grade III-IV) GVHD was deﬁned as 1 positive cell on
either of 2 duplicate slides. For patients with no or mild GVHD
(grade I-II), a positive antigenemia assay was deﬁned as 2 positive
cells/slide. Results: Thirty-four patients were enrolled. Thirteen
patients were not able to proceed after consenting due to positive
antigenemia prior to starting study (3 patients), ﬁnancial reasons (3
patients), severe gut GVHD unabling oral intake (5 patients), or
death (2 patients). Of those who received VGC, the median age
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